LUND, SWEDEN--(Marketwire - November 03, 2011) -
* Laquinimod - Phase III BRAVO trial concluded. Teva plans an additional clinical study before filing a registration application in the US * TASQ - enrolment of patients for Phase III trial ongoing * TASQ - Phase II trial published in Journal of Clinical Oncology * ANYARA - Phase III trial proceeding according to plan * 57-57 - a clinical trial in being prepared in systemic sclerosis * ISI - project is proceeding as planned * RhuDex® - preparations for continued clinical development ongoing * Net sales SEK 231.3 M (8.5) * Operating loss SEK 6.2 M (loss: 149.7) * Loss after tax SEK 1.3 M (loss: 156,8) * Loss per share for the period amounted to SEK 0,02 (loss: 2.40)
This report is also available at www.activebiotech.com
Active Biotech AB Interim Report Jan-Sep 2011: http://hugin.info/1002/R/1560312/482696.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1560312]
For further information, please contact:
Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0) 46-19 11 00
